---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-102543"
form_type: "8-K"
ticker: "PTGX"
cik: "0001377121"
company_name: "Protagonist Therapeutics, Inc"
filed_at: "2021-08-10T23:59:59+00:00"
generated_at: "2026-06-29T16:26:37.036626+00:00"
event_type: "litigation"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Protagonist Therapeutics resolves rusfertide dispute with Zealand Pharma, reduces royalty and milestone payments by 50%

## Summary
- Royalty rate on rusfertide net sales reduced by 50% under settlement agreement.
- All development and sales milestone payments for rusfertide reduced by 50%.
- Company to pay $1.0M (Phase 2b milestone) and $1.5M (Phase 3 milestone) within 2 business days.
- Additional $1.5M payment due in August 2022.
- Future development milestones up to $2.75M; sales milestones up to $50M.

## SEC filing metadata
- accession: 0001104659-21-102543
- form_type: 8-K
- ticker: PTGX
- cik: 0001377121
- company_name: Protagonist Therapeutics, Inc
- filed_at: 2021-08-10T23:59:59+00:00
- event_type: litigation
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1377121/000110465921102543/0001104659-21-102543-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1377121/000110465921102543/tm2124650d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-102543
- JSON: https://secwatch.observer/filing/0001104659-21-102543.json
- Plain text: https://secwatch.observer/filing/0001104659-21-102543.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.